Search

Your search keyword '"Jalving, Mathilde"' showing total 288 results
Start Over Author "Jalving, Mathilde"
288 results on '"Jalving, Mathilde"'

1. Ovarian cancer

Author

Mourits, Marian J. E., Eggink, Florine A., Jalving, Mathilde, de Bruyn, Marco, Bart, Joost, Nijman, Hans W., Steegers, Eric A.P., editor, de Groot, Christianne J.M., editor, Hilders, Carina G.J.M., editor, Hoek, Annemieke, editor, Jaddoe, Vincent W.V., editor, Schoenmakers, Sam, editor, and Zweemer, Ronald P., editor

Published
2024
Full Text
View/download PDF

2. Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers

Author

Stroot, Iris A.S., Bart, Joost, Hollema, Harry, Jalving, Mathilde, Wagner, Marise M., Yigit, Refika, van Doorn, Helena C., de Hullu, Joanne A., Gaarenstroom, Katja N., van Beurden, Marc, van Lonkhuijzen, Luc R.C.W., Slangen, Brigitte F.M., Zweemer, Ronald P., Gómez García, Encarna B., Ausems, Margreet G.E.M., Boere, Ingrid A., van Hest, Liselotte P., Duijkers, Floor A.M., van Asperen, Christi J., Schmidt, Marjanka K., Wevers, Marijke R., Ruijs, Marielle W.G., Devilee, Peter, Collée, J. Margriet, HEBON investigators, de Bock, Geertruida H., and Mourits, Marian J.E.

Published
2024
Full Text
View/download PDF

3. Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Author

Verkerk, Karlijn, Geurts, Birgit S., Zeverijn, Laurien J., van der Noort, Vincent, Verheul, Henk M.W., Haanen, John B.A.G., van der Veldt, Astrid A.M., Eskens, Ferry A.L.M., Aarts, Maureen J.B., van Herpen, Carla M.L., Jalving, Mathilde, Gietema, Jourik A., Devriese, Lot A., Labots, Mariette, Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar, Smit, Egbert F., and Bloemendal, Haiko J.

Published
2024
Full Text
View/download PDF

6. Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol

Author

van der Ploeg, Phyllis, Hendrikse, Cynthia SE., Thijs, Anna MJ., Westgeest, Hans M., Smedts, Huberdina PM., Vos, M Caroline, Jalving, Mathilde, Lok, Christianne AR., Boere, Ingrid A., van Ham, Maaike APC., Ottevanger, Petronella B., Westermann, Anneke M., Mom, Constantijne H., Lalisang, Roy I., Lambrechts, Sandrina, Bekkers, Ruud LM., and Piek, Jurgen MJ.

Published
2024
Full Text
View/download PDF

7. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

Author

Kist de Ruijter, Laura, van de Donk, Pim P., Hooiveld-Noeken, Jahlisa S., Giesen, Danique, Elias, Sjoerd G., Lub-de Hooge, Marjolijn N., Oosting, Sjoukje F., Jalving, Mathilde, Timens, Wim, Brouwers, Adrienne H., Kwee, Thomas C., Gietema, Jourik A., Fehrmann, Rudolf S. N., Fine, Bernard M., Sanabria Bohórquez, Sandra M., Yadav, Mahesh, Koeppen, Hartmut, Jing, Jing, Guelman, Sebastian, Lin, Mark T., Mamounas, Michael J., Eastham, Jeffrey Ryan, Kimes, Patrick K., Williams, Simon P., Ungewickell, Alexander, de Groot, Derk J. A., and de Vries, Elisabeth G. E.

Published
2022
Full Text
View/download PDF

8. The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.

Author

Hoeijmakers, Lotte L., primary, Kuijpers, Anke M.J., additional, van de Wiel, Bart A., additional, Lopez-Yurda, Marta I., additional, Plasmeijer, Elsemieke I, additional, Zuur, Charlotte L., additional, van der Pol, Hanna C., additional, Lucas, Minke W., additional, Romano, Jurriaan, additional, Lijnsvelt, Judith, additional, van den Eertwegh, Alfonsus Johannes Maria, additional, Jalving, Mathilde, additional, Kapiteijn, Ellen, additional, Suijkerbuijk, Karijn, additional, Van Der Veldt, Astrid Aplonia Maria, additional, Jacobs, Bart, additional, de Gruijl, Tanja D, additional, and Blank, Christian U., additional

Published
2024
Full Text
View/download PDF

14. Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation

Author

Zois, Christos E., Hendriks, Anne M., Haider, Syed, Pires, Elisabete, Bridges, Esther, Kalamida, Dimitra, Voukantsis, Dimitrios, Lagerholm, B. Christoffer, Fehrmann, Rudolf S. N., den Dunnen, Wilfred F. A., Tarasov, Andrei I., Baba, Otto, Morris, John, Buffa, Francesca M., McCullagh, James S. O., Jalving, Mathilde, and Harris, Adrian L.

Published
2022
Full Text
View/download PDF

16. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Diéras, Véronique, Han, Hyo S, Kaufman, Bella, Wildiers, Hans, Friedlander, Michael, Ayoub, Jean-Pierre, Puhalla, Shannon L, Bondarenko, Igor, Campone, Mario, Jakobsen, Erik H, Jalving, Mathilde, Oprean, Cristina, Palácová, Marketa, Park, Yeon Hee, Shparyk, Yaroslav, Yañez, Eduardo, Khandelwal, Nikhil, Kundu, Madan G, Dudley, Matthew, Ratajczak, Christine K, Maag, David, and Arun, Banu K

Published
2020
Full Text
View/download PDF

17. Ovarian cancer

Author

Mourits, Marian J. E., Eggink, Florine A., Jalving, Mathilde, de Bruyn, Marco, Bart, Joost, Nijman, Hans W., Steegers, Eric A.P., editor, Fauser, Bart C.J.M., editor, Hilders, Carina G.J.M., editor, Jaddoe, Vincent W.V., editor, Massuger, Leon F.A.G., editor, van der Post, Joris A.M., editor, and Schoenmakers, Sam, editor

Published
2019
Full Text
View/download PDF

18. HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer

Author

de Heer, Ellen C., Jalving, Mathilde, and Harris, Adrian L.

Subjects
Cancer treatment -- Physiological aspects -- Health aspects, Bevacizumab -- Health aspects -- Physiological aspects, Amino acids -- Physiological aspects -- Health aspects, Breast cancer -- Development and progression -- Prognosis, Health care industry
Abstract

Hypoxia-inducible factors (HIFs) and the HIF-dependent cancer hallmarks angiogenesis and metabolic rewiring are well-established drivers of breast cancer aggressiveness, therapy resistance, and poor prognosis. Targeting of HIF and its downstream targets in angiogenesis and metabolism has been unsuccessful so far in the breast cancer clinical setting, with major unresolved challenges residing in target selection, development of robust biomarkers for response prediction, and understanding and harnessing of escape mechanisms. This Review discusses the pathophysiological role of HIFs, angiogenesis, and metabolism in breast cancer and the challenges of targeting these features in patients with breast cancer. Rational therapeutic combinations, especially with immunotherapy and endocrine therapy, seem most promising in the clinical exploitation of the intricate interplay of HIFs, angiogenesis, and metabolism in breast cancer cells and the tumor microenvironment., Introduction Breast cancer is the cancer type with the highest prevalence and, despite therapeutic advances, still has the second highest cancer-related mortality rate in women (1). In breast cancer, low [...]

Published
2020
Full Text
View/download PDF

21. COVID-19 vaccination: the VOICE for patients with cancer

Author

van der Veldt, Astrid A. M., Oosting, Sjoukje F., Dingemans, Anne-Marie C., Fehrmann, Rudolf S. N., GeurtsvanKessel, Corine, Jalving, Mathilde, Rimmelzwaan, Guus F., Kvistborg, Pia, Blank, Christian U., Smit, Egbert F., Lemmens, Valery E. E. P., Hiltermann, T. Jeroen N., Koopmans, Marion P. G., Huckriede, Anke L. W., Rots, Nynke Y., van Els, Cecile A. C. M., van Baarle, Debbie, Haanen, John B. A. G., and de Vries, Elisabeth G. E.

Published
2021
Full Text
View/download PDF

22. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

Author

van Not, Olivier J., primary, Wind, Thijs T., additional, Ismail, Rawa K., additional, Bhattacharya, Arkajyoti, additional, Jalving, Mathilde, additional, Blank, Christian U., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan Willem B., additional, Haanen, John B., additional, Kapiteijn, Ellen, additional, Bloem, Manja, additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Stevense-den Boer, Marion, additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Blokx, Willeke A. M., additional, Suijkerbuijk, Karijn P. M., additional, Fehrmann, Rudolf S. N., additional, and Hospers, Geke A. P., additional

Published
2023
Full Text
View/download PDF

24. Figure S1 from First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Author

Kist de Ruijter, Laura, primary, Hooiveld-Noeken, Jahlisa S., primary, Giesen, Danique, primary, Lub-de Hooge, Marjolijn N., primary, Kok, Iris C., primary, Brouwers, Adrienne H., primary, Elias, Sjoerd G., primary, Nguyen, Margaret T.L., primary, Lu, Hong, primary, Gietema, Jourik A., primary, Jalving, Mathilde, primary, de Groot, Derk J.A., primary, Vasiljeva, Olga, primary, and de Vries, Elisabeth G.E., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table S1 and S2 from First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Author

Kist de Ruijter, Laura, primary, Hooiveld-Noeken, Jahlisa S., primary, Giesen, Danique, primary, Lub-de Hooge, Marjolijn N., primary, Kok, Iris C., primary, Brouwers, Adrienne H., primary, Elias, Sjoerd G., primary, Nguyen, Margaret T.L., primary, Lu, Hong, primary, Gietema, Jourik A., primary, Jalving, Mathilde, primary, de Groot, Derk J.A., primary, Vasiljeva, Olga, primary, and de Vries, Elisabeth G.E., primary

Published
2023
Full Text
View/download PDF

27. End-of-life care for patients with advanced ovarian cancer in the Netherlands

Author

Broekman, K Esther, van der Aa, Maaike A, Nijman, Hans W, Jalving, Mathilde, Reyners, Anna K L, Translational Immunology Groningen (TRIGR), Targeted Gynaecologic Oncology (TARGON), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Ovarian Neoplasms, Terminal Care, Cancer Research, Obstetrics and Gynecology, Carcinoma, Ovarian Epithelial, United States, Aggressive medical care, Death, Oncology, Ovarian cancer, Humans, Female, Registries, Netherlands, Retrospective Studies, End-of-life
Abstract

e17612 Background: Patients with advanced ovarian cancer have a poor prognosis and can experience debilitating abdominal symptoms in the last phase of life. Several analyses, mainly performed in the United States (US), show high rates of chemotherapy administration, and emergency room and hospital visits near the end-of-life in this patient category. No large European studies are available, while the organisation of palliative care differs between the US and Europe and between European countries. We aimed to analyse the intensity of inpatient care near the end-of-life in the Netherlands and perform a cross-study comparison with previous reports. Methods: All patients with ovarian cancer that died in 2016 and 2017 were identified from the database of the foundation Dutch Hospital Data (DHD). For the last six months of life the following parameters of aggressive care were extracted: administration of chemotherapy, emergency room (ER) visits, surgical procedures, hospital and intensive care unit (ICU) admissions. Data were analysed for the cohort as a whole and separately for three age categories: < 60, 60-75 and > 75 years of age. The intensity of inpatient care was compared to previously reported European and US data. Results: A total of 2172 patients died with ovarian cancer in 2016 and 2017 in the Netherlands. Data on medical care use was available for 1775 patients. During the last 6 months of life, chemotherapy was given to half of the ovarian cancer patients and the same percentage of patients was admitted to hospital. Chemotherapy administration near the end-of-life was infrequent, with only 12% of patients receiving chemotherapy in the last month of life. Surgery and ICU admissions in the final 6 months of life were rare (< 10%). Our cohort showed the lowest percentages of all five indicators of aggressive care reported thus far. The use of chemotherapy in the six months prior to death was highest in patients 60-75 years of age compared to younger or older patients. ER visits and hospital admissions were less frequent in patients > 75 years of age compared to the younger age groups. Conclusions: Aggressive medical care use in the final 6 months of life in this Dutch cohort of ovarian cancer patients was lower than in other previously reported cohorts.

Published
2022

29. Phenotype-Guided Targeted Therapy Based on Functional Signal Transduction Pathway Activity in Recurrent Ovarian Cancer Patients: The Stapover Study Protocol

Author

van der Ploeg, Phyllis, primary, Hendrikse, Cynthia, additional, Thijs, Anna, additional, Westgeest, Hans M., additional, Smedts, Huberdina, additional, Vos, Caroline, additional, Jalving, Mathilde, additional, Lok, C.A.R., additional, Boere, Ingrid, additional, van Ham, Maaike, additional, Ottevanger, Nelleke, additional, Westermann, Anneke M., additional, Mom, Constantijne, additional, Lalisang, Roy, additional, Lambrechts, Sandrina, additional, Bekkers, Ruud, additional, and M.J. Piek, Jurgen, additional

Published
2023
Full Text
View/download PDF

35. Postoperative radiotherapy in stage I-III Merkel cell carcinoma

Author

Levy, Sonja, primary, Blankenstein, Stephanie A., additional, Grünhagen, Dirk Jan, additional, Jalving, Mathilde, additional, Hamming-Vrieze, Olga, additional, Been, Lukas B., additional, Tans, Lisa, additional, van Akkooi, Alexander C.J., additional, and Tesselaar, Margot E.T., additional

Published
2022
Full Text
View/download PDF

37. Abstract 5813: Glycogen synthesis as potential novel target in triple negative breast cancer: Glycogen synthase 1 expression in human breast cancers and the impact of downregulation on proliferation of preclinical models

Author

De Heer, Ellen C., primary, Zois, Christos E., additional, Bridges, Esther, additional, Zwager, Mieke C., additional, van der Sluis, Tineke, additional, van der Vegt, Bert, additional, Schröder, Carolien P., additional, de Jong, Steven, additional, Harris, Adrian L., additional, and Jalving, Mathilde, additional

Published
2022
Full Text
View/download PDF

42. Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian Cancer

Author

de Witte, Chris J., primary, Kutzera, Joachim, additional, van Hoeck, Arne, additional, Nguyen, Luan, additional, Boere, Ingrid A., additional, Jalving, Mathilde, additional, Ottevanger, Petronella B., additional, van Schaik-van de Mheen, Christa, additional, Stevense, Marion, additional, Kloosterman, Wigard P., additional, Zweemer, Ronald P., additional, Cuppen, Edwin, additional, and Witteveen, Petronella O., additional

Published
2022
Full Text
View/download PDF

43. The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care.

Author

de Haan-Du, Jing, Groenier, Klaas H., Wauben-Spaetgens, Brendy, Jalving, Mathilde, Kleefstra, Nanne, Landman, Gijs W. D., and de Bock, Geertruida H.

Abstract

Background: Poor glycemic control prior to cancer diagnosis for patients with preexisting type 2 diabetes (T2DM) may predict a worse cancer diagnosis. We investigated the association between pre-diagnosis glycemic control and all-cause mortality in patients with T2DM who develop cancer. Methods: This prospective cohort study linked data from three sources covering 1989 to 2019: a T2DM benchmarking database, the Netherlands Cancer Registry, and the Personal Records Database. We included patients with T2DM and incident primary breast, colorectal, or prostate cancer (stage 0-III), with target glycemic control defined according to Dutch guidelines. Analysis involved estimating the association between glycemic control and all-cause mortality with Cox proportional hazard models, accounting for individual expected survival relative to the general population and relevant disease (e.g., diabetes duration and medications) and individual (e.g., age and gender) characteristics. Results: Of the 71,648 linked cases, 620 had breast cancer, 774 had colorectal cancer, and 438 had prostate cancer, with follow-up data available for 6.4 (4.2-8.4), 5.6 (2.7-7.6), and 6.3 (4.5-8.2) years, respectively. Compared with patients with pre-diagnosis glycemic control at target, the HRs and 95% confidence intervals for mortality among those with pre-diagnosis glycemic control not at target were 1.40 (1.00-1.96) for breast cancer, 1.45 (1.12-1.88) for colorectal cancer, and 1.39 (0.98-1.98) for prostate cancer. Conclusions: Among patients with T2DM in Dutch primary care, poor glycemic control before diagnosis with breast and colorectal cancer can increase mortality compared with good control. Impact: Glycemic control prior to cancer diagnosis is of prognostic value. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer

Author

Eggen, Annemarie C, primary, Richard, Nadine M, additional, Bosma, Ingeborg, additional, Jalving, Mathilde, additional, Leighl, ; Natasha B, additional, Liu, Geoffrey, additional, Mah, Kenneth, additional, Higazy, Randa, additional, Shultz, David B, additional, Reyners, Anna K L, additional, Rodin, Gary, additional, and Edelstein, Kim, additional

Published
2021
Full Text
View/download PDF

49. A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors

Author

Gan, Hui K., primary, Millward, Michael, additional, Jalving, Mathilde, additional, Garrido-Laguna, Ignacio, additional, Lickliter, Jason D., additional, Schellens, Jan H.M., additional, Lolkema, Martijn P., additional, Van Herpen, Carla L.M., additional, Hug, Bruce, additional, Tang, Lihua, additional, O'Connor-Semmes, Robin, additional, Gagnon, Robert, additional, Ellis, Catherine, additional, Ganji, Gopinath, additional, Matheny, Christopher, additional, and Drilon, Alexander, additional

Published
2021
Full Text
View/download PDF

50. First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Author

Kist de Ruijter, Laura, primary, Hooiveld-Noeken, Jahlisa S., additional, Giesen, Danique, additional, Lub-de Hooge, Marjolijn N., additional, Kok, Iris C., additional, Brouwers, Adrienne H., additional, Elias, Sjoerd G., additional, Nguyen, Margaret T.L., additional, Lu, Hong, additional, Gietema, Jourik A., additional, Jalving, Mathilde, additional, de Groot, Derk J.A., additional, Vasiljeva, Olga, additional, and de Vries, Elisabeth G.E., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results